Keyphrases
Anti-IL-17
10%
Change from Baseline
10%
Disability Health
10%
Durable Response
10%
Etanercept
30%
Fully Human
10%
Health Assessment Questionnaire Disability Index (HAQ-DI)
30%
High Response Rate
10%
IL-17 Antibody
10%
Interleukin
10%
Moderate-to-severe Psoriasis
10%
Once-weekly
10%
PASI 75
20%
Phase II Trial
10%
Physical Function
100%
Physical Functioning
20%
Placebo
30%
Plaque Psoriasis
100%
Psoriasis
30%
Psoriasis Disease
10%
Psoriatic Arthritis
100%
Randomized Phase III Trial
100%
Rapid Onset
10%
Response Rate
10%
Secukinumab
100%
Twice Daily
10%
Medicine and Dentistry
Cytokine
20%
Disease
10%
Etanercept
30%
Health Assessment Questionnaire
30%
Monoclonal Antibody
10%
Placebo
30%
Psoriasis
40%
Psoriasis Vulgaris
100%
Psoriatic Arthritis
100%
Secukinumab
100%
Symptom
10%
Pharmacology, Toxicology and Pharmaceutical Science
Cytokine
20%
Disease
10%
Etanercept
30%
Monoclonal Antibody
10%
Placebo
30%
Psoriasis
40%
Psoriasis Vulgaris
100%
Psoriatic Arthritis
100%
Secukinumab
100%
Symptom
10%
Immunology and Microbiology
Cytokine
20%
Etanercept
30%
Interleukin
10%
Monoclonal Antibody
10%
Psoriatic Arthritis
100%
Secukinumab
100%